Companies /Healthcare

Bioventus Inc - Class A

NASDAQ: BVS Medical Devices
$13.79
▼ $0.18 (−1.29%) today
Markets closed · 8:31pm ET

Q4 2025 Earnings

Reported Mar 5, 2026, 7:34am ET · SEC source
$0.24
Beat +10.75%
EPS · est. $0.22
$157.9M
Beat +1.91%
Revenue · est. $154.9M
+0.4%
Beating market
BVS vs S&P since report
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−8%−4%0Mar 5Mar 6report 7:34am ETearnings−1.5%−9.9%
−8%−4%0Mar 5Mar 6earnings−1.5%−9.9%
BVS −9.9%S&P 500 −1.5%
−8%−4%0Mar 5Mar 6report 7:34am ETearnings−1.1%−9.9%
−8%−4%0Mar 5Mar 6earnings−1.1%−9.9%
BVS −9.9%NASDAQ −1.1%
−8%−4%0Mar 4Mar 13report 7:34am ETearnings−2.0%−5.4%
−8%−4%0Mar 4Mar 13earnings−2.0%−5.4%
BVS −5.4%S&P 500 −2.0%
−8%−4%0Mar 4Mar 13report 7:34am ETearnings−1.3%−5.4%
−8%−4%0Mar 4Mar 13earnings−1.3%−5.4%
BVS −5.4%NASDAQ −1.3%
+7.44%
Day of report
−7.58%
Next session
−5.49%
One week
−2.86%
30 days

S&P 500 over the same 30 days: −3.24%.

Did BVS Beat Earnings? Q4 2025 Results

Bioventus capped fiscal 2025 with a notably strong fourth quarter, posting adjusted EPS of $0.24 against a consensus estimate of $0.22 while reporting revenue of $157.90 million, up 2.8% year-over-year on a reported basis and 10.0% organically. The profitability turnaround was the headline story: the company swung to GAAP net income attributable to Bioventus of $14.76 million from a net loss of $388,000 in Q4 2024, powered by double-digit organic growth in both Pain Treatments and Surgical Solutions, gross margin expansion to a non-GAAP 75.5%, and disciplined cost controls that widened non-GAAP operating margin to 21.1% from 16.9%. Pain Treatments was the standout, generating $79.66 million in revenue, up 15.1%, on robust demand for hyaluronic acid viscosupplementation therapies. Full-year operating cash flow rose 92% to $74.67 million, with the company also reducing debt by $29.00 million in the quarter. Looking ahead, management guided 2026 net sales of $600 million to $610 million and adjusted EPS of $0.73 to $0.77, reflecting continued above-market growth expectations.

Key Takeaways
  • Strong demand for differentiated hyaluronic acid therapies for knee osteoarthritis drove Pain Treatments growth
  • Higher U.S. demand for Bone Graft Substitutes supported Surgical Solutions
  • Improved commercial effectiveness and sales force execution with EXOGEN Bone Stimulation System
  • Gross margin expansion with non-GAAP gross margin improving to 75.5% from 73.7%
  • Disciplined spending and cost management
  • 10.0% organic revenue growth across the portfolio

“Our team delivered strong fourth quarter performance, concluding an important year in which we strengthened our portfolio, drove above-market growth, improved margins, and strengthened our balance sheet. These results reflect continued demand for our market-leading therapies, and disciplined execution across our commercial and operational initiatives. We are entering 2026 from a position of strength and plan to invest to further accelerate our growth while expanding profitability and generating meaningful cash flow. We believe this is a powerful combination that positions Bioventus to deliver increased shareholder value.”

Bioventus CEO, on the earnings call

Forward Guidance & Outlook

For full-year 2026, Bioventus expects net sales of $600 million to $610 million (approximately 6% to 7% growth), adjusted EPS of $0.73 to $0.77 (approximately 7% to 13% growth), and cash from operations of $82 million to $87 million. The guidance reflects continued above-market revenue growth, higher earnings, and robust cash generation.

BVS YoY Financials

Revenue$157.9M
Gross Profit$108.8M
Operating Income$19.5M
Net Income$17.3M

BVS Revenue by Segment

Pain Treatments$79.7M+15.1%
Surgical Solutions$55.5M+3.4%
Restorative Therapies$22.7M−26.0%

BVS Revenue by Geography

United States$139.5M+3.2%
Rest of World$18.4M−0.1%

Figures from SEC filings and company reports. Not investment advice.